These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interleukin-18 promoter polymorphisms in patients with systemic lupus erythematosus.
    Author: Warchoł T, Lianeri M, Olesińska M, Jagodziński PP.
    Journal: Clin Exp Rheumatol; 2011; 29(2):310-3. PubMed ID: 21470492.
    Abstract:
    OBJECTIVES: The role of various polymorphisms located in the IL-18 promoter has not yet been defined with regards to patient susceptibility to SLE, and occurrence of clinical manifestations of the disease remains inconsistent. METHODS: Using PCR-RFLP and DNA sequencing analysis we studied the frequency of -137 G/C (rs187238), -607 C/A (rs1946518) and -1297C/T (rs360719) polymorphisms in IL-18 promoter in patients with SLE from a sample of the Polish population. RESULTS: We observed that patients with SLE bearing the IL-18 -1297CC genotype exhibited a 2.536-fold increased risk of SLE incidence (95% CI=1.333-4.826, p=0.0035). We also found a significantly higher frequency of the IL-18 -1297C allele in patients than in controls, with odds ratio (OR) for the IL-18 -1297C allele in patients with SLE being 1.558 (95% CI=1.189-2.041, p=0.0013). Moreover, there was an association between the IL-18 -1297CC genotype and renal manifestations of SLE, OR=3.792 (1.446-9.947, p=0.0051). However, we did not find any contribution of the IL-18 -607 C/A and -137 G/C polymorphisms to SLE incidence or occurrence of the studied SLE manifestations. CONCLUSIONS: Our findings confirmed that the IL-18 -1297C gene variant may contribute to the risk of SLE incidence. Moreover, IL-18 -1297CC might be associated with renal manifestations of SLE.
    [Abstract] [Full Text] [Related] [New Search]